Back

Effectiveness of cardiac telerehabilitation with relapse prevention compared to centre-based cardiac rehabilitation: results from the SmartCare-CAD randomised controlled trial

15 April 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Young Investigators Award Secondary Prevention and Rehabilitation Cardiovascular Rehabilitation EAPC Premium Access ESC Preventive Cardiology 2021

About the speaker

Photo
Mr Rutger Brouwers

Catharina Hospital, Eindhoven (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Physical activity and sedentary behaviour in cardiovascular disease patients during the COVID-19 lockdown in the Netherlands; a longitudinal cohort study
Mr B. van Bakel (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Lifestyle management and compliance in coronary patients: The gender gap. Results from the ESC EORP EUROASPIRE V survey
Mr P. Vynckier (Ghent, BE)
Abstract Slides Video
Presentation thumbnail
Cardiac rehabilitation and all-cause mortality in patients with heart failure: A retrospective cohort study
Doctor B. Buckley (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus
Doctor H. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Low skeletal muscle density combined with muscle dysfunction predicts adverse events after adult cardiovascular surgery
Mr M. Yamashita (Sagamihara, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigators Award Secondary Prevention and Rehabilitation
Video

The Event

Event poster

ESC Preventive Cardiology 2021

15 April - 17 April 2021
You may be interested in
thumbnail
Congress Session
How to prescribe exercise for people with valvular heart disease or hypertension
thumbnail
Congress Presentation
How should we prescribe exercise – and who should do it?
thumbnail
Congress Presentation
Exercise and cardiovascular risk: friend or foe? - discussion

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources